Description: CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.
Home Page: www.csl.com.au
655 Elizabeth Street
Melbourne,
VIC
3000
Australia
Phone:
61 3 9389 1911
Officers
Name | Title |
---|---|
Dr. Paul F. McKenzie Ph.D. | MD, CEO & Executive Director |
Ms. Joy Carolyn Linton B.Com., BComm, GAICD, Grad Dip AFI | Interim Executive Vice President of CSL Behring |
Mr. Andy Schmeltz | Executive Vice President of CSL Behring Business Unit (Leave of Absence) |
Mr. John A. G. Levy CPA | Interim Chief Financial Officer |
Chris Cooper | Head of Investor Relations |
Mr. Gregory Boss B.S., BS(Hons), J.D. | Executive VP of Legal & General Counsel |
Ms. Roanne Parry | Chief Human Resources Officer |
Dr. Andrew D. Nash BSc (Hons), GAICD, Ph.D. | Senior Vice President of Research |
Dr. William Mezzanotte M.D., M.P.H. | Executive VP & Head of Research and Development |
Mr. Mark Hill B.A., M.B.A. | Chief Digital Information Officer & Executive VP |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
GIC Sector: | Health Care |
---|---|
GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
GIC Industry: | Biotechnology |
GIC Sub-Industry: | Biotechnology |
Forward PE: | 32.4675 |
---|---|
Trailing PE: | 32.6848 |
Price-to-Book MRQ: | 4.9593 |
Price-to-Sales TTM: | 5.638 |
IPO Date: | |
Fiscal Year End: | June |
Full Time Employees: | 32698 |